After markets closed Monday, Devon Energy reported quarterly results that beat on both the top and bottom lines. The oil and gas producer did not indicate that it planned to increase production or capital spending. Shares traded up 6% in mid-morning action Tuesday. Diamondback Energy also beat top-line and bottom-line consensus estimates. Shares were up about 3.2% Tuesday.

Fertilizer maker Mosaic missed both profit and revenue estimates. The company said it expects second-quarter pricing for its phosphate products to be $140 to $160 per metric ton higher than in the first quarter and potash prices to be $40 to $60. Shares traded up almost 3% Tuesday morning.

Pipeline operator Williams beat estimates on both the top and bottom lines. The company said it expects to increase its dividend this year from $1.64 per share (yield of 4.9%) to $1.70. Shares traded up 0.6%.

Before markets opened on Tuesday, BP reported better-than-expected earnings but a miss on revenue. The oil giant also said it would buy back $2.5 billion in stock before it announced second-quarter results. Shares traded up 6.3% on Tuesday.

Marathon Petroleum beat top-line and bottom-line estimates, and shares traded up 2.7%. The refiner did not raise its buyback spending or its dividend.

Paramount Global beat the consensus earnings estimate but missed on revenue. Shares traded down about 5.0%.

Pfizer beat estimates on the top and bottom lines but issued downside guidance for earnings and revenue for the full 2022 fiscal year. Shares traded up about 2.0%.

After markets close Tuesday, Airbnb, AMD and Livent will report quarterly results. We also have previewed expectations for Albemarle, APA, Barrick Gold and Cameco.

Here is a look at four more companies set to report results Wednesday or Thursday.

ConocoPhillips

Over the past 12 months, shares of ConocoPhillips (NYSE: COP) have added about 94% to their value. As with both Chevron and Exxon Mobil, the rise in the share price of the country’s largest independent oil and gas producer is closely tied to the rising price of oil. The company reports results before markets open on Thursday.

Since late September, crude oil prices have risen by nearly 65%. Because Conoco is not saddled with refining or marketing divisions, the price of crude pushes its share price up even faster than either Exxon’s (up 59.3% over the past year) or Chevron’s (up 62.5%).

Of the 27 brokerages covering the stock, 23 have ratings of Buy or Strong Buy. Three more rate the shares at Hold. At a recent price of around $96.90 a share, the upside potential based on a median price target of $124.50 is about 28.5%. At the high price target of $160, the upside potential is 65.1%.

For the first quarter, analysts are expecting revenue of $18.36 billion, which would be up 15% sequentially and nearly 74% higher year over year. Adjusted earnings per share (EPS) are expected to come in at $3.22, up 41.7% sequentially and 367% higher year over year. For the full 2022 fiscal year, Conoco is expected to report EPS of $13.00, up 116.3%, on sales of $69.22 billion, up 43.2%.

Conoco stock trades at 7.4 times expected 2022 EPS, 8.6 times estimated 2023 earnings of $11.23 and 10.3 times estimated 2024 earnings of $9.38 per share. The stock’s 52-week range is $51.41 to $107.52. The company pays an annual dividend of $1.42 (yield of 1.49%). Total shareholder return for the past 12 months was 95.7%. Investors are going to want to hear about bigger returns, preferably from a dividend increase, but a heftier buyback would do as well.

Over the past 12 months, shares of COVID-19 vaccine maker Moderna Inc. (NASDAQ: MRNA) have slipped by about 20.6%. Over the past two years, the stock is up almost 210%, including a spike to an all-time high in early August of last year, when shares were up 950% for the two-year period. The company reports results Wednesday morning.

In recent developments, the company has applied to sell its coronavirus vaccine to treat children between the ages of 6 months and 6 years. It also got a boost from rival Pfizer’s announcement last week that the Dow company’s Paxlovid did not prove effective against COVID-19.

Of 20 brokerages covering the stock, nine rate the stock at Buy or Strong Buy and five have Hold ratings. At a share price of around $144.60, the implied upside to a median price target of $210 is 45.2%. Based on a high price target of $506, the upside potential on the stock is 250%.

Analysts expect Moderna to report first-quarter revenue of $4.43 billion, down more than 38% sequentially and 128% year over year. Adjusted EPS are forecast at $5.62, down about 50% sequentially and down more than 10% year over year. For the full 2022 fiscal year, EPS are currently expected to come in at $27.73, down 2%, on sales of $22.34 billion, up nearly 21%.

Moderna stock trades at 5.1 times expected 2022 EPS, 14.6 times estimated 2023 earnings of $9.61 and 28.9 times estimated 2024 earnings of $4.83. The stock’s 52-week range is $122.01 to $497.49. Moderna does not pay a dividend, and total shareholder return for the past year was negative 24.9%.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Uber

Over the past year, shares of Uber Technologies Inc. (NYSE: UBER) have declined by almost 46%. The stock’s 52-week high was set exactly a year ago, and the stock has bounced around a steadily downward trend since then. The company is scheduled to report results after markets close on Wednesday.

Uber said in March that demand had reached about 90% of the pre-pandemic level in February and also raised the mid-point of its first-quarter EBITDA guidance by $25 million. The company also initiated a fuel surcharge to help its drivers meet the rising cost of gasoline, but that is set to expire soon and the knock-on effect may be that drivers will begin looking elsewhere for work. Adding more incentives would be costly.

Analysts remain solidly bullish on Uber. Of 46 brokerages covering the stock, 40 give the stock a Buy or Strong Buy rating and 5 more have a Hold rating. At a share price of around $29.50, the potential upside based on a median price target of $55 is 86.4%. At the high target of $80, the upside potential is 117%.

The consensus revenue estimate for the first quarter is $6.1 billion, up 5.6% sequentially and 110% higher year over year. Uber is expected to post a loss per share of $0.11 in the quarter, compared with the prior quarter’s EPS of $0.64 and last year’s EPS of $0.45. For the full 2022 fiscal year, analysts expect a loss per share of $0.13, compared with last year’s EPS of $0.33, on revenue of $27.22 billion, up almost 56%.

Uber’s stock trades at 42.6 times estimated 2023 earnings of $0.69 and 30.7 times estimated 2024 earnings of $0.95 per share. The stock’s 52-week range is $28.28 to $56.13. Uber does not pay a dividend. Total shareholder return for the past 12 months is negative 46.7%.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.